These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22161106)

  • 41. [Comparison of standard prognostic factors with the deletion of 13q14 detected by interphase fluorescence in situ hybridization on separated and unseparated bone marrow cells in multiple myeloma].
    Smejkalová J; Vranová V; Oltová A; Kuglík P; Filková H; Heinigová J; Kovárová L; Adam Z; Krejcí M; Pour L; Büchler T; Svobodník A; Vostrejsová S; Kalábová V; Vorlícek J; Penka M; Hájek R
    Cas Lek Cesk; 2005; 144(7):483-8. PubMed ID: 16161543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Application of FICTION technique to the detection of genetic aberrations in multiple myeloma].
    Wang D; Huang L; Zhang H; Geng Z; Shang Z; Zhou JF; Li CR
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):226-30. PubMed ID: 21569703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma.
    Huang TJ; Huang BJ; Liang QW; Huang CW; Fang Y
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):62-8. PubMed ID: 14969840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
    Grzasko N; Hus M; Chocholska S; Pluta A; Hajek R; Dmoszynska A
    Leuk Lymphoma; 2012 Dec; 53(12):2500-3. PubMed ID: 22497640
    [No Abstract]   [Full Text] [Related]  

  • 45. Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System.
    Sagaster V; Kaufmann H; Odelga V; Ackermann J; Gisslinger H; Rabitsch W; Zojer N; Ludwig H; Nösslinger T; Zielinski C; Drach J
    Eur J Haematol; 2007 Mar; 78(3):227-34. PubMed ID: 17253972
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of chromosome 13 deletions by fluorescent in situ hybridization.
    VanWier S; Fonseca R
    Methods Mol Med; 2005; 113():59-69. PubMed ID: 15968095
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
    Shaughnessy JD; Haessler J; van Rhee F; Anaissie E; Pineda-Roman M; Cottler-Fox M; Hollmig K; Zangari M; Mohiuddin A; Alsayed Y; Grazziutti M; Epstein J; Crowley J; Barlogie B
    Br J Haematol; 2007 Jun; 137(6):530-6. PubMed ID: 17489983
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The comparison of three cytogenetic methods for detecting multiple myeloma].
    Ren J; Yang LH; Li GX; Fan JL; Hou J
    Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):737-40. PubMed ID: 20079209
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of 14q32 rearrangements in multiple myeloma, using simultaneous FISH analysis combined with immunofluorescence.
    Abaza HM; Youssef SR; Saad AA; Kamal GM; Hegazy MG; Ibrahim RI; Annaka LM
    Hematol Oncol Stem Cell Ther; 2015 Jun; 8(2):56-63. PubMed ID: 25929730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression.
    Sewify EM; Afifi OA; Mosad E; Zaki AH; El Gammal SA
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):215-22. PubMed ID: 24468132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray.
    Wang Y; Wu MC; Sham JS; Zhang W; Wu WQ; Guan XY
    Cancer; 2002 Dec; 95(11):2346-52. PubMed ID: 12436441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma.
    Balcárková J; Urbánková H; Scudla V; Holzerová M; Bacovský J; Indrák K; Jarosová M
    Cancer Genet Cytogenet; 2009 Jul; 192(2):68-72. PubMed ID: 19596256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
    Fonseca R; Van Wier SA; Chng WJ; Ketterling R; Lacy MQ; Dispenzieri A; Bergsagel PL; Rajkumar SV; Greipp PR; Litzow MR; Price-Troska T; Henderson KJ; Ahmann GJ; Gertz MA
    Leukemia; 2006 Nov; 20(11):2034-40. PubMed ID: 17024118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
    Mohan M; Gong Z; Ashby TC; Al Hadidi S; Thanendrarajan S; Schinke C; Alapat D; Shaughnessy JD; Zhan F; van Rhee F; Sawyer JR; Tian E; Zangari M
    Cancer; 2023 Aug; 129(16):2491-2498. PubMed ID: 37282609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.
    Schmidt-Wolf IG; Glasmacher A; Hahn-Ast C; Jüttner A; Schnurr T; Cremer F; Moehler T; Goldschmidt H; Busert B; Schubert R; Schwanitz G
    Cancer Genet Cytogenet; 2006 May; 167(1):20-5. PubMed ID: 16682281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multicolor interphase cytogenetics for the study of plasma cell dyscrasias.
    Sáez B; Martín-Subero JI; Odero MD; Prosper F; Cigudosa JC; Schoch R; Calasanz MJ; Siebert R
    Oncol Rep; 2007 Nov; 18(5):1099-106. PubMed ID: 17914559
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes.
    Tabernero D; San Miguel JF; Garcia-Sanz M; Nájera L; García-Isidoro M; Peréz-Simon JA; Gonzalez M; Wiegant J; Raap AK; Orfão A
    Am J Pathol; 1996 Jul; 149(1):153-61. PubMed ID: 8686739
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
    Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
    Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.